

Chronic Kidney Disease Market Report 2032: Epidemiology Data, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Gender-specific diagnosed prevalent cases of CKD were higher in females as compared to males in 2022 in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, March 23, 2024 /EINPresswire.com/ -- DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Chronic Kidney Disease Market Forecast](#)

Some of the key facts of the Chronic Kidney Disease Market Report:

The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

In February 2023, the US Food and Drug Administration approved JESDUVROQ tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. However, in July 2023, the company withdrew its application from the EMA.

In April 2023, the European Commission approved VAFSEO (vadadustat) for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis.

Key Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc, Lexicon Pharmaceuticals, Sanofi, and many others.

Key Chronic Kidney Disease Therapies: Renal Autologous Cell Therapy (REACT), Bardoxolone methyl, Ziltivekimab, Semaglutide, JARDIANCE (empagliflozin), KBP-5074, KT-301, CIN-107 (Baxdrostat), Zibotentan, ALLN-346, DM199, Sotagliflozi, and others

The total market size of CKD in the 7MM was approximately USD 4,934 million in 2022 and is projected to increase during the forecast period (2023-2032)

The market size in the 7MM will increase at a CAGR of 8.7% due to increasing prevalent cases of

the disease and launch of the emerging therapies.

In 2022, the Chronic Kidney Disease market reached its peak size in the US among the 7MM, totaling approximately USD 2,566 million, while it was at its lowest in Italy, amounting to USD 115 million. It is expected that these figures will rise by 2032.

The largest proportion of prevalent CKD patients were estimated to be in the US, followed by EU4, the UK, and Japan. In the US alone, the number of diagnosed CKD patients was estimated to be 5.5 million.

The overall market size of CKD treatment is projected to grow throughout the forecast period (2023-2032) due to the emergence of new treatments such as Renal Autologous Cell Therapy (REACT), empagliflozin, KBP-5074, ziltivekimab, bardoxolone methyl, and semaglutide.

In terms of gender-specific diagnosed prevalent cases of CKD in the 7MM in 2022, females accounted for a higher number of cases (approximately 8,320 thousand) compared to males (around 7,790 thousand).

According to DelveInsight estimates, the US accounted for approximately 5.6 million diagnosed cases whereas in the EU4 and the UK, there were around 6.9 million diagnosed CKD cases in 2022. Japan accounted for 3.5 million diagnosed cases of CKD in 2022. These cases are expected to increase in the US, EU4 and the UK, and expected to decrease in Japan by 2032.

Among the EU4 and the UK, the UK had the highest diagnosed prevalent population of CKD (approximately 2.3 million cases), followed by Germany (approximately 1.5 million cases) in 2022. On the other hand, Italy (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

CKD has been identified as a female-dominant disease; in our analysis, the number of females suffering was higher than males. In 2022, 52% cases of CKD were of females, while 48% cases were of males in the 7MM.

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

Chronic Kidney Disease Overview

Chronic kidney disease arises when the kidneys sustain damage, leading to a diminished ability to filter blood effectively. It is characterized by persistent abnormalities in kidney structure or function lasting more than three months, negatively impacting health. The condition is classified into five phases based on the degree of kidney damage and function, ranging from modest impairment in stage 1 to complete kidney failure in stage 5. The severity of chronic kidney disease can vary.

In the early stages of the disease, symptoms are typically absent. Diagnosis often occurs incidentally through blood or urine tests conducted for other purposes, revealing kidney issues. Advanced stages may manifest symptoms such as fatigue, swelling in the ankles, feet, or hands, shortness of breath, general malaise, and blood in the urine. Various tests, including blood and urine analyses, are employed to detect chronic kidney disease. The eGFR blood test assesses

kidney function efficiency, while imaging examinations such as ultrasound, CT scans, X-rays, and MRIs aid in diagnosis.

Chronic Kidney Disease Epidemiology

DelveInsight estimates that there were approximately 16 million diagnosed prevalent cases of chronic kidney disease in the 7MM in 2022.

As per our analysis, chronic kidney disease has been identified as a female-dominant disease, with more females suffering than males. In 2022, 52% of cases of CKD were of females, while 48% of cases were of males in the 7MM.

The chronic kidney disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Chronic Kidney Disease Prevalent Cases

Chronic Kidney Disease Diagnosed Prevalent Cases

Chronic Kidney Disease Gender-specific Diagnosed Prevalent Cases

Chronic Kidney Disease Age-specific Diagnosed Prevalent cases

Chronic Kidney Disease Complication-specific Diagnosed Prevalent cases

Chronic Kidney Disease Stage-specific Diagnosed Prevalent Cases

Chronic Kidney Disease Etiology-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ [Chronic Kidney Disease Epidemiology Forecast](#)

Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Kidney Disease market or expected to get launched during the study period. The analysis covers Chronic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Kidney Disease Therapies

Renal Autologous Cell Therapy (REACT)
Bardoxolone methyl
Ziltivekimab
Semaglutide
JARDIANCE (empagliflozin)
KBP-5074
KT-301
CIN-107 (Baxdrostat)
Zibotentan
ALLN-346
DM199
Sotagliflozi

Chronic Kidney Disease Key Companies

ProKidney
Reata Pharmaceuticals
Novo Nordisk A/S
Boehringer Ingelheim
Eli Lilly and Company
KBP Biosciences
Kibow Pharma
Cincor Pharma
AstraZeneca
Allena Pharmaceuticals
DiaMedica Therapeutics
Lexicon Pharmaceuticals
Sanofi

Discover more about therapies set to grab major Chronic Kidney Disease market share @ [Chronic Kidney Disease Treatment Landscape](#)

Chronic Kidney Disease Treatment Market Landscape

There are various types of drugs in the chronic kidney disease market. Although available medications cannot cure CKD, they can treat problems and halt future kidney damage. DelveInsight's chronic kidney disease market projection focuses on pharmacological therapy (including all presently utilized off-label medications) recommended for chronic kidney disease management and excludes revenue produced by devices and surgical procedures, including dialysis.

The chronic kidney disease drugs market is classified for the study based on drug class, such as

erythropoietin stimulating agents (ESA), angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers (ACE-I and ARBs), antidiabetics, secondary hyperparathyroidism treatment (SHPT), and urate-lowering therapies. There are also approved therapies for chronic kidney disease treatment, such as KERENDIA, INVOKANA, JYNARQUE, and FARXIGA.

According to DelveInsight's analysis, antidiabetics and antihypertensives are the most widely utilized among the top prescribed pharmaceuticals. Given the health risks associated with renal dysfunction, DelveInsight analysts developed a comprehensive understanding of chronic kidney disease and its etiologies, defining the breadth of the therapeutic paradigm. The chronic kidney disease treatment market is classified into three segments: diabetic kidney disease (DKD), polycystic kidney disease (PKD), and hypertension induced kidney disease.

Scope of the Chronic Kidney Disease Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Chronic Kidney Disease Companies: Dana-Farber Cancer Institute, Huabo Biopharm Co., Ltd., Beijing Scitech-Mq Pharmaceuticals, Oxford BioMedica, Hutchison Medipharma Limited, Takeda, Amgen, Novartis, AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Pfizer, Calithera Biosciences, Inc, AbbVie, Bristol-Myers Squibb, Abbott, SCRI Development Innovations, LLC, Astellas Pharma Inc, and others

Key Chronic Kidney Disease Therapies: Renal Autologous Cell Therapy (REACT), Bardoxolone methyl, Ziltivekimab, Semaglutide, JARDIANCE (empagliflozin), KBP-5074, KT-301, CIN-107 (Baxdrostat), Zibotentan, ALLN-346, DM199, Sotagliflozi, and others

Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies

Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

Table of Contents

1. Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Chronic Kidney Disease
3. SWOT analysis of Chronic Kidney Disease
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Chronic Kidney Disease Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2019–2032)
14. Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Chronic Kidney Disease Market Drivers
16. Chronic Kidney Disease Market Barriers
17. Chronic Kidney Disease Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Chronic Kidney Disease Pipeline

"Chronic Kidney Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Kidney Disease market. A detailed picture of the Chronic Kidney Disease pipeline landscape is provided, which includes the disease overview and Chronic Kidney Disease treatment guidelines.

Chronic Kidney Disease Epidemiology

DelveInsight's 'Chronic Kidney Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Kidney Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management

Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kritika Rehani

Email: info@delveinsight.com

Contact No.: +14699457679

City: 304 S. Jones Blvd #2432, Las Vegas

State: Nevada (89107)

Country: United States

Website: <https://www.delveinsight.com/consulting>

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/697662316>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.